Jun. 23, 2026
An interdisciplinary team of Northern faculty and student researchers is developing a new test that shows promise in diagnosing certain brain cancers quickly, affordably and non-invasively. Their work revolves around a novel biosensor called D2HGlo. When mixed with bodily fluids such as urine, plasma and serum, the tool lights up like a fluorescent beacon when it detects the presence of an abnormal molecule that plays a key role in tumor development. This “liquid biopsy” method could improve outcomes and reduce the physical and emotional toll on brain cancer patients.